US EditionNovo Nordisk Shares Extend Losses, Erasing Nearly All Gains Since Wegovy Launch
9 Articles
9 Articles
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy.
"Of course it's serious when Trump goes out and puts pressure like this."
The darkest week in history in the Danish pharmaceutical listing closes with a new corrective. Donald Trump’s pressure today plunges Novo Nordisk’s quote to a minimum of four years. Read
Novo Nordisk's nightmare week began with a sharp reduction in the full-year forecast and the announcement of a new CEO. Trump's new demands fuel the decline on Friday.
The Danish pharmaceutical giant will receive new price blows at the stock exchange opening today.
Novo Nordisk shares hit 4-year low, Trump urges US drug price cuts - Regional Media News
(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States. Friday’s drop brings this week’s losses for Novo to more than 30% – marking its worst-ever weekly fall – after it slashed its outlook for 2025 sales growth and appointed veteran insider Maziar Mike Doustdar as its new CEO. (…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
